Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer



Status:Completed
Conditions:Cervical Cancer, Cancer, Endometrial Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:September 2012
End Date:January 2016

Use our guide to learn which trials are right for you!

A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma

This phase II trial studies how well dalantercept works in treating patients with endometrial
cancer that has come back or is persistent. Dalantercept may stop the growth of endometrial
cancer by blocking blood flow to the tumor.

PRIMARY OBJECTIVES:

I. To estimate the proportion of patients with persistent or recurrent endometrial cancer who
survive progression-free for at least 6 months and the proportion of patients who have
objective tumor response (complete or partial), treated with dalantercept (ACE-041).

II. To determine the nature and degree of toxicity of dalantercept in this cohort of
patients.

SECONDARY OBJECTIVES:

I. To estimate progression-free survival (PFS) and overall survival (OS) of patients with
persistent or recurrent endometrial cancer treated with dalantercept.

TERTIARY OBJECTIVES:

I. To measure the expression of vascular endothelial growth factor (VEGF), fibroblast growth
factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β),
activin receptor-like kinase 1 (ALK1), endoglin (CD105), and other markers via
immunohistochemistry (IHC) and determine if there is correlation between expression and
clinical response to treatment.

II. To determine the correlation between ALK1 gene expression, other markers, and clinical
response to treatment.

III. To determine the correlation between concentration of VEGF, bone morphogenetic protein 9
(BMP9), bone morphogenetic protein 10 (BMP10), and ALK1 in pre-cycle 1 plasma using an
enzyme-linked immunosorbent assay (ELISA), and clinical response to treatment.

IV. To correlate somatic mutations in candidate genes with response to therapy.

OUTLINE:

Patients receive dalantercept subcutaneously (SC) on day 1. Courses repeat every 21 days in
the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.

Inclusion Criteria:

- Patients must have recurrent or persistent endometrial carcinoma; histologic
confirmation of the original primary tumor is required

- Patients with the following histologic epithelial cell types are eligible:
Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma,
clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not
otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma,
and transitional cell carcinoma

- All patients must have measurable disease; measurable disease is defined by Response
Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) as at least one lesion that
can be accurately measured in at least one dimension (longest diameter to be
recorded); each lesion must be >= 10 mm when measured by computed tomography (CT),
magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or >= 20 mm
when measured by chest x-ray; lymph nodes must be > 15 mm in short axis when measured
by CT or MRI

- Patients must have at least one "target lesion" to be used to assess response on this
protocol as defined by RECIST version 1.1; tumors within a previously irradiated field
will be designated as "non-target" lesions unless progression is documented or a
biopsy is obtained to confirm persistence at least 90 days following completion of
radiation therapy

- Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG)
protocol, if one exists; in general, this would refer to any active GOG phase III
protocol or rare tumor protocol for the same patient population

- Patients who have received one prior regimen must have a GOG performance status of 0,
1, or 2; patients who have received two prior regimens must have a GOG performance
status of 0 or 1

- Recovery from effects of recent surgery, radiotherapy, or chemotherapy

- Patients should be free of active infection requiring antibiotics (with the
exception of uncomplicated urinary tract infection [UTI])

- Any hormonal therapy directed at the malignant tumor must be discontinued at
least one week prior to registration

- Any other prior therapy directed at the malignant tumor, including chemotherapy
and immunologic agents, must be discontinued at least three weeks prior to
registration; any investigational drug must be discontinued at least 30 days
prior to registration

- Any prior radiation therapy must be discontinued at least four weeks prior to
registration

- At least 4 weeks must have elapsed since the patient underwent any major surgery
(e.g., major: laparotomy, laparoscopy); there is no delay in treatment for minor
procedures (e.g., central venous access catheter placement)

- Prior therapy

- Patients must have had one prior chemotherapeutic regimen for management of
endometrial carcinoma. Initial treatment may include chemotherapy, chemotherapy
and radiation therapy, and/or consolidation/maintenance therapy; chemotherapy
administered in conjunction with primary radiation as a radio-sensitizer WILL be
counted as a systemic chemotherapy regimen

- Patients are allowed to receive, but are not required to receive, one additional
cytotoxic regimen for management of recurrent or persistent disease

- Patients must have NOT received any non-cytotoxic (biologic or targeted) agent(s)
for management of recurrent or persistent disease; prior non-cytotoxic (biologic
or targeted) agent(s) is allowed as part of initial treatment; prior hormonal
therapy is allowed, but must be discontinued at least one week prior to
registration

- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcL

- Platelets greater than or equal to 100,000/mcL

- Hemoglobin greater than or equal to 9 g/dL

- Creatinine less than or equal to 1.5 times institutional upper limit normal (ULN)

- Sodium greater than or equal to 130 mEq/L (Common Terminology Criteria for Adverse
Events [CTCAE] v. 4, grade 0 or 1)

- Urine protein should be screened by urinalysis; if protein is 2+ or higher, 24-hour
urine protein should be obtained and the level should be < 1,000 mg (< 1.0 g/24 hrs)
for patient enrollment

- Bilirubin less than or equal to 1.5 times ULN

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal
to 3 times ULN

- Alkaline phosphatase less than or equal to 3 times ULN

- Albumin greater than or equal to 3 (CTCAE v. 4, grade 0 or 1)

- Prothrombin time (PT) such that international normalized ratio (INR) is less than or
equal to 1.5 times ULN (or an in-range INR, usually between 2 and 3, if a patient is
on a stable dose of therapeutic warfarin)

- Partial thromboplastin time (PTT) less than or equal to 1.5 times ULN

- Left ventricular ejection fraction (LVEF) greater than 50% (measured by echocardiogram
or MUGA [multi-gated acquisition] scan)

- Patients must have signed an approved informed consent and authorization permitting
release of personal health information

- Patients must meet pre-entry requirements

- Patients of childbearing potential must have a negative serum pregnancy test prior to
the study entry and be practicing an effective form of contraception

Exclusion Criteria:

- Patients who have had prior therapy with dalantercept or other inhibitor of the ALK1
pathway

- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer and other specific malignancies, are excluded if there is any
evidence of other malignancy being present within the last three years; patients are
also excluded if their previous cancer treatment contraindicates this protocol therapy

- Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis OTHER THAN for the treatment of endometrial cancer within the last three
years are excluded; prior radiation for localized cancer of the breast, head and neck,
or skin is permitted, provided that it was completed more than three years prior to
registration, and the patient remains free of recurrent or metastatic disease

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER
THAN for the treatment of endometrial cancer within the last three years are excluded;
patients may have received prior adjuvant chemotherapy for localized breast cancer,
provided that it was completed more than three years prior to registration, and that
the patient remains free of recurrent or metastatic disease

- Patients with history or evidence upon physical exam of central nervous system disease
(CNS) disease, including primary brain tumor, seizures not controlled with standard
medical therapy, or any brain metastases or leptomeningeal disease

- Serious or non-healing wound, ulcer, or bone fracture

- History of abdominal fistula or anastomotic leak, gastrointestinal perforation, or
intra-abdominal abscess within 6 months of registration

- Patients requiring parenteral hydration or parenteral/total parenteral nutrition

- No patients with:

- Active bleeding (e.g., active hemoptysis, defined as bright red blood of greater
than or equal to ½ teaspoon [2.5 ml] in any 24-hour period) within 2 weeks prior
to registration or gastrointestinal bleeding within 3 months prior to
registration

- Hereditary hemorrhagic telangiectasia (HHT)

- Platelet function abnormality

- Autoimmune or hereditary hemolysis

- Coagulopathy, or

- Tumor involving major vessels (defined as any lesion invading or abutting the
wall [i.e., no fat plane evident] of major blood vessels as assessed by CT or
MRI)

- Patients receiving treatment with full-dose aspirin (325 mg oral daily), clopidogrel
(Plavix), or dabigatran (Pradaxa)

- Patients with peripheral edema greater than or equal to grade 1 within 4 weeks of
registration

- No patients with clinically significant cardiovascular disease:

- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm
Hg despite antihypertensive medications

- Evidence of hypertrophic cardiomyopathy

- New York Heart Association (NYHA) class II or greater congestive heart failure
(CHF)

- Any of the following within 6 months prior to study registration:

- Bypass surgery

- Stent placement

- Myocardial infarction

- Acute coronary syndrome/unstable angina

- Hospitalization for congestive heart failure (CHF)

- Serious cardiac arrhythmia requiring medication; this does not include
asymptomatic atrial fibrillation with controlled ventricular rate

- Prolonged QTc interval > 450 ms

- Prior anthracycline cumulative dose > 450 mg/m^2

- Patients who are pregnant or nursing

- History of syndrome of inappropriate antidiuretic hormone secretion (SIADH)

- Patients who have undergone a therapeutic paracentesis within 4 weeks of registration

- Known history of positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV)
surface antigen (HBsAg), or HBV core antibody, or human immunodeficiency virus (HIV)
antibody results

- History of severe (National Cancer Institute-Common Terminology Criteria for Adverse
Events [NCI-CTCAE] v.4.0 >= grade 3) allergic or anaphylactic reaction or
hypersensitivity to recombinant proteins or excipients (10 mM Tris buffered saline) in
the investigational agent

- Clinically significant active pulmonary risk including pulmonary hypertension,
pulmonary embolism, or history of pulmonary edema
We found this trial at
30
sites
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
Elkton, Maryland 21921
?
mi
from
Elkton, MD
Click here to add this to my saved trials
Indianapolis, Indiana 46260
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
424 Savannah Rd
Lewes, Delaware 19958
(302) 645-3300
Beebe Medical Center Located in beautiful historic Lewes, Delaware, near Rehoboth Beach, Beebe Healthcare offers...
?
mi
from
Lewes, DE
Click here to add this to my saved trials
Mayfield Heights, Ohio 44124
?
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
9485 Mentor Ave
Mentor, Ohio 44060
(440) 205-5755
Lake University Ireland Cancer Center Lake Health is a private, not-for-profit leader in community health...
?
mi
from
Mentor, OH
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
4755 Ogletown-Stanton Road
Newark, Delaware 19718
302-733-1000
Christiana Care Health System - Christiana Hospital A 913-bed, 1.3-million-square-foot, modern facility in Newark, Delaware,...
?
mi
from
Newark, DE
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orlando, Florida 32803
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Portland, Maine 04102
?
mi
from
Portland, ME
Click here to add this to my saved trials
Providence, Rhode Island 02905
?
mi
from
Providence, RI
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94115
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
1700 S Tamiami Trail
Sarasota, Florida 34239
(941) 917-9000
Sarasota Memorial Hospital Sarasota Memorial Health Care System, an 806-bed regional medical center, is among...
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Seattle, Washington 98133
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1305 W 18th St
Sioux Falls, South Dakota 57117
(605) 333-1000
Sanford USD Medical Center - Sioux Falls Sanford
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
1309 W 17th Street
Sioux Falls, South Dakota 57104
(605) 328-8000
Sanford Cancer Center-Oncology Clinic Sanford Health is an integrated health system headquartered in the Dakotas...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials